High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)

Creative Commons License

Bengala C., Guarneri V., Ledermann J., Rosti G., Wandt H., Lotz J., ...Daha Fazla

BONE MARROW TRANSPLANTATION, cilt.36, sa.1, ss.25-31, 2005 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 36 Sayı: 1
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1038/sj.bmt.1705007
  • Dergi Adı: BONE MARROW TRANSPLANTATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.25-31
  • Anahtar Kelimeler: ovarian cancer, complete remission, high-dose consolidation chemotherapy, haemopoietic growth factors, GYNECOLOGIC-ONCOLOGY-GROUP, PROGENITOR-CELL TRANSPLANTATION, MINIMAL RESIDUAL DISEASE, RANDOMIZED-TRIAL, INTRAPERITONEAL CISPLATIN, INTRAVENOUS CISPLATIN, PHASE-III, PROGNOSTIC-FACTORS, COMPLETE RESPONSE, G-CSF
  • Ankara Üniversitesi Adresli: Evet

Özet

The majority of advanced ovarian cancer patients achieve an objective response following chemotherapy; however, only 20 - 30% are in remission after 5 years. Intraperitoneal or high- dose chemotherapy ( HDC) may prolong disease- free and overall survival ( OS) in patients with platinum- sensitive, small volume disease. To better de. ne the subsets of patients who might benefit from HDC, we performed a retrospective analysis on 91 patients in 1st complete remission ( CR) treated from 21 centres of the EBMT group. At a median follow- up of 48 months, median time- to- progression ( TTP) and OS were 21.2 and 44.4 months, respectively. Tumour grade, stage, residual disease, disease status before HDC, type and year of transplant, source of haemopoietic progenitors and use of haemopoietic growth factors ( HGF) after transplant were analysed for TTP and OS. The only significant parameter was the use of HGF: median OS for patients receiving or not receiving HGF was 46.2 vs 17.8 months, respectively ( P: 0.035); this difference was maintained after multivariate analysis ( P: 0.02). Our analysis does not identify any subgroup of patients in 1st CR who can benefit from HDC; however, median survival of patient with no residual disease has not been reached. The role of HGF after HDC deserves further investigation.